在患有家族性高胆固醇血症的儿童中使用静止剂治疗:越年轻,越好
Jessica Rodenburg1, Maud N Vissers, Albert Wiegman
1Academic Medical Centre, Department of Vascular Medicine, University of Amsterdam, The Netherlands.
Circulation
|August 1, 2007
概括
在患有家族性高胆固醇血症的儿童中,早期使用他类药物治疗显著降低了动脉内心介质厚度 (IMT) 的进展. 这项长期研究证实,早期开始服用他类药物对预防青少年动脉样硬化有益.
科学领域:
- 心血管医学 心血管医学
- 儿科内分泌学 儿科内分泌学
- 药理学 药理学是指药理学的学科.
背景情况:
- 之前的随机试验表明,在患有家族性高胆固醇血症的儿童中,普拉瓦斯塔丁可逆转心室内介质厚度 (IMT).
- 启动了长期随访研究,以评估他类药物启用年龄对心血管IMT的影响.
- 在儿科患者中长期使用他类药物治疗的安全性也得到了评估.
研究的目的:
- 探索他类药物开始的年龄与动脉IMT之间的关系.
- 评估普拉瓦斯塔丁治疗在患有家族性高胆固醇血症儿童的长期安全性和疗效.
主要方法:
- 从先前的安慰剂对照试验中对214名儿童的随访,其中186人提供了分析数据.
- 儿童在初步研究后继续接受普拉瓦斯塔丁治疗 (20或40毫克).
- 在平均4.5年内,监测了心内脉的IMT测量和安全参数 (脂质,实验室测试).
主要成果:
- 开始服用他类药物的年龄是随访后 carotid IMT 的独立预测因素.
- 较早启动他类药物治疗与较小的动脉IMT有关.
- 没有报告任何严重的实验室不良事件;他类药物治疗没有影响性成熟.
结论:
- 在青少年和年轻成年人中,早期启动他类药物治疗会延迟动脉IMT的进展.
- 这项研究提供了证据表明,在患有家族性高胆固醇血清症的儿童早期使用他类药物治疗可以预防青春期的动脉样硬化.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
833
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
833
Cholesterol: Significance and Regulation
2.1K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
2.1K
Pharmacokinetics in Pediatric Patients: Drug Metabolism
414
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
414
Pharmacokinetics in Pediatric Patients: Drug Excretion
413
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
413
Atherosclerosis III: Management
747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747


